PHAXIAM Therapeutics

formed in 2023 from Pherecydes' merger with Erytech, PHAXIAM aimed to build a 35-45-phage GMP bank covering the most critical resistant pathogens by end-2026, with commercial IV and orthopedic-infection programs.…

Country
France
Discontinued
Coverage
CNEUUS
therapeutics-platforms✓✓✓
Regulatorsfdaemanmpa

Verifiable facts

FactValueSource
Funding€7.8 million capital increase settled in July 2024live.euronext.com · globenewswire.com
CapacityAiming for a portfolio of 25 GMP phages by end-2025 and 35-45 GMP phages by end-2026live.euronext.com · businesswire.com
Regulatory approvalIND approval from US FDA in Q4 2024 for the GLORIA studylive.euronext.com · businesswire.com · globenewswire.com
Production siteHeadquarters in Lyon, France; collaboration with Technophage for manufacturingprospeo.io
HeadcountEstimated between 32 and 100 employees medium confidenceprospeo.io
RevenueTargeting €20 million in revenue in 2027live.euronext.com · businesswire.com

Independent sources: businesswire.com · globenewswire.com · live.euronext.com · prospeo.io

Technologies
NameClusterRisk
Bacteriophage therapytherapeutics-platformsHigh→

Compiled by BIOECON from primary sources.

Compliance Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.